Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Phathom Pharmaceuticals, Inc. - Common Stock
(NQ:
PHAT
)
15.71
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Phathom Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
↗
February 10, 2023
Via
Benzinga
Where Phathom Pharmaceuticals Stands With Analysts
↗
February 10, 2023
Via
Benzinga
Phathom Pharma Shares Fall After Formal FDA Request For Vonoprazan Data
↗
February 10, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
February 10, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
February 09, 2023
Via
Benzinga
Phathom Pharmaceuticals Provides Regulatory Updates
February 09, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
BMO Capital Maintains Outperform Rating for Phathom Pharmaceuticals: Here's What You Need To Know
↗
January 04, 2023
Via
Benzinga
TOP RANKED ROSEN LAW FIRM Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT
February 09, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Credit Acceptance, and Phathom and Encourages Investors to Contact the Firm
February 03, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Why Shares of Phathom Pharmaceutical Jumped This Week
↗
January 28, 2023
Investors are reading between the lines to see if the company is fixing its problems regarding its lead therapy.
Via
The Motley Fool
Seagate, Boot Barn, Tesla And Other Big Stocks Moving Higher On Thursday
↗
January 26, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Phathom, Super Micro, and Fate and Encourages Investors to Contact the Firm
January 18, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
January 11, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
↗
January 09, 2023
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion.
Via
Benzinga
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
January 08, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Dow Gains 150 Points After Fed Minutes
↗
January 04, 2023
U.S. stocks traded higher toward the end of trading, following the release of minutes from the FOMC meeting.
Via
Benzinga
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
January 04, 2023
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
January 04, 2023
Via
Benzinga
Nasdaq Rises Over 100 Points; Crude Oil Drops Sharply
↗
January 04, 2023
U.S. stocks extended gains midway through trading, with the Dow Jones gaining around 250 points on Wednesday ahead of the release of minutes from the Fed's meeting.
Via
Benzinga
US Stocks Open Higher Ahead Of Fed Minutes; Dow Rises 100 Points
↗
January 04, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Wednesday.
Via
Benzinga
FDA Issues No Action Notice For Phathom Pharma's Investigational Candidate, Shares Plunge
↗
January 04, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
January 04, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
January 04, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!
Via
InvestorPlace
Vera Therapeutics, Phathom Pharmaceuticals And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
↗
January 04, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
January 03, 2023
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
↗
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
↗
December 13, 2022
Gainers OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.
Via
Benzinga
NASDAQ:PHAT Shareholder Alert: Investigation over Possible Securities Laws Violations by Phathom Pharmaceuticals, Inc.
↗
November 15, 2022
San Diego, CA -- (SBWIRE) -- 11/15/2022 -- Phathom Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 08, 2022
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
November 03, 2022
From
Phathom Pharmaceuticals
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.